Douleur et Analgésie

, Volume 26, Issue 3, pp 158–169

Apport des blocs et cathétérismes périmédullaires: données de la littérature et conduites pratiques

Revue de la Littérature / Literature Review

Résumé

L’analgésie intrathécale est une technique efficace pour soulager les douleurs cancéreuses rebelles. Sa mise en œuvre nécessite de connaître la physiologie de l’espace intrathécal et les différentes molécules utilisables. Le rapport bénéfice/risque est analysé à partir des données publiées. Des considérations pratiques sont abordées pour utiliser cette technique efficace dans de bonnes conditions de sécurité.

Mots clés

Analgésie médullaire Analgésie intrathécale Douleur cancer 

Spinal analgesia in cancer pain: what’s evidence and how to carry out?

Abstract

Intrathecal or epidural therapy is an effective way to alleviate intractable cancer pain. Intrathecal therapy is mainly used over long periods, epidural for shorter treatments. To implement it, the physiology of intrathecal space and the pharmacodynamics of the different used drugs need to be known.

The clinical results with different published trials are analysed. Then, the practical considerations are discussed to carry out these techniques safely.

Keywords

Spinal analgesia Intrathecal therapy Cancer pain 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Ackerman LL, Follett KA, Rosenquist RW, et al (2003) Longterm outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 26:668–677PubMedCrossRefGoogle Scholar
  2. 2.
    Alicino I, Giglio M, Manca F, et al (2012) Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain 153:245–249PubMedCrossRefGoogle Scholar
  3. 3.
    American Society of Anesthesiologists Task Force on Neuraxial Opioids, Horlocker TT, Burton AW, et al (2009) Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration. Anesthesiology 110:218–230PubMedGoogle Scholar
  4. 4.
    Aprili D, Bandschapp O, Rochlitz C, et al (2009) Serious complications associated with external intrathecal catheters used in cancer pain patients: a systematic review and meta-analysis. Anesthesiology 111:1346–1355PubMedCrossRefGoogle Scholar
  5. 5.
    Atli A, Theodore BR, Turk DC, et al (2010) Intrathecal opioid therapy for chronic non malignant pain: a retrospective cohort study with 3-year follow-up. Pain Med 11:1010–1016PubMedCrossRefGoogle Scholar
  6. 6.
    Atweh SF, Kuhar MJ (1977) Autoradiographic localization of opiate receptors in rat brain. I. Spinal cord and lower medulla. Brain Res 124:53–67PubMedCrossRefGoogle Scholar
  7. 7.
    Ballantyne JC, Carwood CM (2005) Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev (1):CD005178Google Scholar
  8. 8.
    Bennett G, Burchiel K, Buchser E, et al (2000) Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000. J Pain Symptom Manage 20: S37–S43PubMedCrossRefGoogle Scholar
  9. 9.
    Bernards CM (2002) Understanding the physiology and pharmacology of epidural and intrathecal opioids. Best Pract Res Clin Anaesthesiol 16:489–505PubMedCrossRefGoogle Scholar
  10. 10.
    Bernards CM (2006) Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 105:169–178PubMedCrossRefGoogle Scholar
  11. 11.
    Burton AW, Rajagopal A, Shah HN, et al (2004) Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med 5:239–247PubMedCrossRefGoogle Scholar
  12. 12.
    Buvanendran A (2011) Intrathecal Drug Delivery for Pain and Spasticity. Saunders, PhiladelphiaGoogle Scholar
  13. 13.
    Chambers WA (2008) Nerve blocks in palliative care. Br J Anaesth 101:95–100PubMedCrossRefGoogle Scholar
  14. 14.
    Christo PJ, Mazloomdoost D (2008) Interventional pain treatments for cancer pain. Ann N Y Acad Sci 1138:299–328PubMedCrossRefGoogle Scholar
  15. 15.
    Coffey RJ, Owens ML, Broste SK, et al (2009) Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology 111:881–891PubMedCrossRefGoogle Scholar
  16. 16.
    Dahm P, Lundborg C, Janson M, et al (2000) Comparison of 0.5% intrathecal bupivacaine with 0.5% intrathecal ropivacaine in the treatment of refractory cancer and non cancer pain conditions: results from a prospective, crossover, double-blind, randomized study. Reg Anesth Pain Med 25:480–487PubMedGoogle Scholar
  17. 17.
    De Kock M, Lavand’homme P, Waterloos H, et al (2005) The short-lasting analgesia and long-term antihyperalgesic effect of intrathecal clonidine in patients undergoing colonic surgery. Anesth Analg 101:566–572PubMedCrossRefGoogle Scholar
  18. 18.
    Deer TR, Krames ES, Hassenbusch SJ, et al (2007) Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 10:300–328PubMedCrossRefGoogle Scholar
  19. 19.
    Deer TR, Levy R, Prager J, et al (2012) Polyanalgesic Consensus Conference—2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation 15:467–482PubMedCrossRefGoogle Scholar
  20. 20.
    Deer TR, Prager J, Levy R, et al (2012) Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 15:436–464PubMedCrossRefGoogle Scholar
  21. 21.
    Deer TR, Prager J, Levy R, et al (2012) Polyanalgesic Consensus Conference—2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation 15:483–495PubMedCrossRefGoogle Scholar
  22. 22.
    Deer TR, Prager J, Levy R, et al (2012) Polyanalgesic Consensus Conference 2012. Neuromodulation 15:418–419PubMedCrossRefGoogle Scholar
  23. 23.
    Deer TR, Prager J, Levy R, et al (2012) Polyanalgesic Consensus Conference—2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 15:420–435PubMedCrossRefGoogle Scholar
  24. 24.
    Deer TR, Smith HS, Burton AW, et al (2011) Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician 14: E283–E312PubMedGoogle Scholar
  25. 25.
    van Dongen RT, Crul BJ, van Egmond J (1999) Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 15:166–172PubMedCrossRefGoogle Scholar
  26. 26.
    Duarte RV, Raphael JH, Southall JL, et al (2010) Intrathecal inflammatory masses: is the yearly opioid dose increase an early indicator? Neuromodulation 13:109–113PubMedCrossRefGoogle Scholar
  27. 27.
    Dupoiron D, Bore F, Lefebvre-Kuntz D, et al (2012) Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician 15:395–403PubMedGoogle Scholar
  28. 28.
    Dupoiron D, Lefebvre-Kuntz D, Brenet O, et al (2011) Douleur chronique cancéreuse et analgésie intrathécale: expérience de trois centres de lutte contre le cancer. Douleurs 12:140–146Google Scholar
  29. 29.
    Ellis DJ, Dissanayake S, McGuire D, et al (2008) Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: A prospective, open-label study. Neuromodulation 11:40–49PubMedCrossRefGoogle Scholar
  30. 30.
    Follett KA (2003) Intrathecal analgesia and catheter-tip inflammatory masses. Anesthesiology 99:5–6PubMedCrossRefGoogle Scholar
  31. 31.
    Hassenbusch SJ, Gunes S, Wachsman S et al (2002) Intrathecal clonidine in the treatment of intractable pain: a phase I/II study. Pain Med 3:85–91PubMedCrossRefGoogle Scholar
  32. 32.
    Hassenbusch SJ, Portenoy RK, Cousins M, et al (2003) Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery—report of an expert panel. J Pain Symptom Manage 27:540–563CrossRefGoogle Scholar
  33. 33.
    Kedlaya D, Reynolds L, Waldman S, et al (2002) Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol 16:651–665PubMedCrossRefGoogle Scholar
  34. 34.
    Maier C, Gockel HH, Gruhn K, et al (2011) Increased risk of suicide under intrathecal ziconotide treatment? — a warning. Pain 152:235–237PubMedCrossRefGoogle Scholar
  35. 35.
    Melzack R, Wall PD (1965) Pain mechanisms: a new theory. Science 150:971–979PubMedCrossRefGoogle Scholar
  36. 36.
    Mercadante S, Intravaia G, Villari P, et al (2007) Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 23:793–798PubMedCrossRefGoogle Scholar
  37. 37.
    Mion G, Ruttimann M, Daniel L (1997) Kétamine à doses infraanesthésiques pour le traitement d’une douleur de type neuropathique. Ann Fr Anesth Reanim 16:81–82PubMedCrossRefGoogle Scholar
  38. 38.
    Pert CB, Snyder SH (1973) Opiate receptor: demonstration in nervous tissue. Science 179:1011–1014PubMedCrossRefGoogle Scholar
  39. 39.
    Raffaeli W, Righetti D, Caminiti A, et al (2008) Implantable intrathecal pumps for the treatment of noncancer chronic pain in elderly population: drug dose and clinical efficacy. Neuromodulation 11:33–39PubMedCrossRefGoogle Scholar
  40. 40.
    Rauck RL, Cherry D, Boyer MF, et al (2003) Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 4:441–447PubMedCrossRefGoogle Scholar
  41. 41.
    Rauck RL, Wallace MS, Leong MS, et al (2006) A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 31:393–406PubMedCrossRefGoogle Scholar
  42. 42.
    Reig E, Abejon D (2009) Continuous morphine infusion: a retrospective study of efficacy, safety, and demographic variables. Neuromodulation 12:122–129PubMedCrossRefGoogle Scholar
  43. 43.
    Ruan X (2007) Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician 10:357–366PubMedGoogle Scholar
  44. 44.
    Shields DE, Liu W, Gunning K, et al (2008) Statistical evaluation of the chemical stability of ziconotide solutions during simulated intrathecal administration. J Pain Symptom Manage 36:e4–e6PubMedCrossRefGoogle Scholar
  45. 45.
    Shields D, Montenegro R (2007) Chemical stability of ziconotideclonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation. 10(Suppl 1): 6–11PubMedCrossRefGoogle Scholar
  46. 46.
    Shields D, Montenegro R, Aclan J, et al (2007) Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation 10(Suppl 1):1–5PubMedCrossRefGoogle Scholar
  47. 47.
    Shields D, Montenegro R, Ragusa M, et al (2005) Chemical Stability of Admixtures Combining Ziconotide with Morphine or Hydromorphone During Simulated Intrathecal Administration. Neuromodulation 8:257–263PubMedCrossRefGoogle Scholar
  48. 48.
    Smith TJ, Coyne PJ (2003) How to use implantable intrathecal drug delivery systems for refractory cancer pain. J Support Oncol 1:73–76PubMedGoogle Scholar
  49. 49.
    Smith TJ, Staats PS, Deer T, et al (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040–4049PubMedCrossRefGoogle Scholar
  50. 50.
    Smith TJ, Staats PS, Deer T, et al (2005) An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 16:825–833PubMedCrossRefGoogle Scholar
  51. 51.
    Staats PS, Yearwood T, Charapata SG, et al (2004) Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291:63–70PubMedCrossRefGoogle Scholar
  52. 52.
    Stearns L, Boortz-Marx R, Du Pen S, et al (2005) Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol 3: 399–408PubMedGoogle Scholar
  53. 53.
    Vranken JH, Troost D, de Haan P, et al (2006) Severe toxic damage to the rabbit spinal cord after intrathecal administration of preservative-free S(+)-ketamine. Anesthesiology 105:813–818PubMedCrossRefGoogle Scholar
  54. 54.
    Wallace MS, Charapata SG, Fisher R, et al (2006) Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 9:75–86PubMedCrossRefGoogle Scholar
  55. 55.
    Wallace MS, Rauck RL, Deer T, et al (2010) Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain 26:635–644PubMedCrossRefGoogle Scholar
  56. 56.
    Webster LR, Fakata KL, Charapata S, et al (2008) Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 9:282–290PubMedCrossRefGoogle Scholar
  57. 57.
    Webster LR, Fisher R, Charapata S, et al (2009) Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage 37:363–372PubMedCrossRefGoogle Scholar
  58. 58.
    Yaksh TL (1987) Spinal opiates: a review of their effect on spinal function with emphasis on pain processing. Acta Anaesthesiol Scand Suppl 85:25–37PubMedCrossRefGoogle Scholar
  59. 59.
    Yaksh TL (1997) Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand 41(1 Pt 2):94–111PubMedCrossRefGoogle Scholar
  60. 60.
    Yaksh TL, de Kater A, Dean R, et al (2012) Pharmacokinetic analysis of ziconotide (SNX-111) an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. Neuromodulation 15:508–519PubMedCrossRefGoogle Scholar

Copyright information

© Médecine et Hygiène et Springer-Verlag France 2013

Authors and Affiliations

  1. 1.Unité d’anesthésie douleur, institut de cancérologie de l’Ouestcentre Paul-PapinAngers cedexFrance
  2. 2.Centre d’évaluation et de traitement de la douleur, bâtiment ACHU Saint-Étiennecedex 02France

Personalised recommendations